Merck Ignores Molnupiravir’s Cytotoxicity

https://defyccc.com/wp-content/uploads/Molnupiravir-Cytotoxic-TSN-postprint.pdf

Cytotoxicity

Molnupiravir is a mutagenic [2] [3] [4] [5] [6] nucleotide analogue, and its potential cytotoxicity and genotoxicity are not in doubt [7]. Its use for some categories of patients could be justified if benefits were exceeding harm and risk. Instead, Merck elected to deny the existence of these risks.

Molnupiravir’s metabolites cause mutations in human DNA [4], just like they do in viral RNA. This is not in question. If the rate of mutations at therapeutic doses were sufficiently low, Merck should have shown that. Merck’s researchers dismissed this danger by alleging that they had conducted tests showing an absence of cytotoxicity [8], without showing any data. Their response was rebutted [7] [9] and laughed at by other scientists [9].

The therapeutic dosage 800 mg, twice daily, for 5 days is at the upper limit of the investigated range

50 - 800 mg [10], suggesting it is higher than what was initially expected.

Molnupiravir was initially developed to treat Equine Encephalitis virus diseases, and its most valuable property was its ability to cross the brain-body barrier and achieve high concentration in the brain and very high concentrations in the spleen [11] . Its concentration in the spleen is higher than in the lungs showed that meaningful inhibition of SARS-COV-2 without cytotoxicity is impossible in Vero cells (Fig.1B) . The data for human epithelial cells is inconsistent but does suggest cytotoxicity.

More Mercky Business

Merck researchers admitted to the necessity of in-vivo mutagenicity studies for this drug before proceeding to human trials. They, therefore, claimed that such studies (Pig-a and the Big Blue® (cII Locus)) have been conducted and that no danger of mutagenicity was found even at higher doses [12]. This is highly unlikely. Moreover, other scientists argued that these studies had significant limitations and do not allow Merck to make such claims [9]. To make matters worse, Merck failed to publish any data from these studies, making it impossible to peer review or replicate them. This raises suspicions not only about the toxicity of Molnupiravir, but also about Merck’s conduct before and during clinical trials.

==No data about concentrations and effects of Molnupiravir’s metabolites in the most vulnerable tissues,

such as bone marrow, can be found==

Pelase read entire pdf.